Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder.
Yohann Loriot
No relevant relationships to disclose
Karim Fizazi
Other Remuneration - Karim Fizazi
Joan Carles
No relevant relationships to disclose
Garry Alan Weems
Employment or Leadership Position - Allos Therapeutics
Stock Ownership - Allos Therapeutics
Lacey Chance
Employment or Leadership Position - Allos Therapeutics
Stock Ownership - Allos Therapeutics
Neeraj Agarwal
No relevant relationships to disclose